Drug intelligence / Profile preview

Diclonile Cream

Development stage: Unknown
Lead developer: Nilegenix
Modality: Small Molecules
Administration: Topical

Overview

Diclonile Cream is a topical small molecule analgesic and anti-inflammatory medication marketed by Nilegenix, a generic pharmaceutical company based in Sangli, India. It is indicated for the relief of muscle pain and joint pain. Although the specific active ingredients are not explicitly detailed in the company's commercial listing, the name is indicative of diclofenac, a nonsteroidal anti-inflammatory drug (NSAID). The product is an approved generic formulation intended for local application to reduce inflammation and pain at the site of musculoskeletal injury or condition.

Brand names: Diclonile Cream
Other names: Diclonile

Targets

PTGS2 (Prostaglandin-Endoperoxide Synthase 2)PGHS-1 (Prostaglandin G/H Synthase 1)

Beyond the preview

Go deeper on Diclonile Cream.

Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.

Clinical trials

Follow clinical development from study design and recruitment through results.

Trial phase
Status
Readouts

Indications & development

Explore development by indication, patient population, and geography.

Indications
Development status
Countries

Licensing & deals

Trace asset ownership, licensing agreements, and commercial partnerships.

Partners
Deal terms
Milestones

Patents & exclusivity

Explore the patent landscape and regulatory exclusivity around an asset.

Patents
Expiration dates
Exclusivity

Competitive landscape

Compare development programs by target, modality, and indication.

Competing assets
Targets
Development stage

Research & analysis

Connect source evidence and development news to your research questions.

Publications
News
Analysis

Bring the full picture into focus.

See how Gosset can support your research on Diclonile Cream.

Explore the full profile